Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Dupilumab
Monoclonal Antibody · Asthma, Obstructive airway disease
Monoclonal AntibodyAsthma, Obstructive airway disease
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Manufacturer advises use only if potential
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Dupilumab is a human IgG4 monoclonal antibody that targets the interleukin-4 (IL-4) receptor. By binding to the IL-4 receptor, it inhibits signaling pathways of both IL-4 and interleukin-13 (IL-13), which are critical cytokines in type 2 inflammation associated with allergic and inflammatory conditions.
Indications
AsthmaObstructive airway diseaseatopic dermatitismoderate-to-severe atopic dermatitismaintenance treatment of moderate-to-severe asthma with eosinophilic phenotype or glucocorticoid-dependent asthmamaintenance treatment of chronic rhinosinusitis with nasal polyposismoderate to severe eczemaReduced exacerbation rate in symptomatic COPD patients with high exacerbation risk and elevated blood eosinophils of at least 300 cells per microliter, when added to triple inhaled therapy
Dosing
- Adult
- symptoms; the dose may need to be repeated after 12 hours if necessary. For severe croup not effectively controlled with corticosteroid treatment, nebulised adrenaline/epinephrine p.…
Side effects
Common
conjunctivitiskeratitisblepharitisdry eye
Serious
- Serious systemic eosinophilia (most frequently associated with the reduction of oral corticosteroids)
Pregnancy & lactation
Pregnancy
Manufacturer advises use only if potential
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Etanercept
Severe
Database
Clinical effect not specified
Source: DDInter
Fingolimod
Severe
Database
Clinical effect not specified
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Mumps Virus Strain B Level Jeryl Lynn Live Antigen
Severe
Database
Clinical effect not specified
Source: DDInter
Natalizumab
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Dupilumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e, BNF·Verified: 2026-05-13 · House clinical team